It's All About-Research Funding-Indianapolis-Undertand The Type One
JDRF is the only organization with a strategic research plan to end T1D. Our strategies include: Artificial Pancreas Systems Artificial pancreas systems will eliminate blood glucose testing and carb counting by totally automating insulin dosing, initially preventing dangerous low blood sugars and eventually ensuring ideal glucose control. Complications JDRF’s complications research is leading to therapies to treat and even reverse some of the debilitating, costly, and life-threatening complications caused by T1D. Encapsulation JDRF’s encapsulation research will restore insulin independence for 18 months to two years
by implanting newly created beta cells into a protective capsule, which eliminates the need for toxic immune suppression therapies. Full list of Video Credits is stored here http://broadcaster.beazil.net/public/credits/youtube/videos/41822 Living with T1D is a constant balancing act. People with T1D must regularly monitor their blood-sugar level, inject or continually infuse insulin through a pump, and carefully balance their insulin doses with eating and daily activities throughout the day and night.
T1D is a serious and stressful disease to manage. Treatment options are improving all the time, and people with T1D are able to lead normal, productive and inspiring lives. JDRF is driving research to improve the technology people with T1D use to monitor blood-sugar levels and deliver the proper doses of insulin, as well as research that will ultimately deliver a cure. But even with intensive disease management, a significant portion of their day is still spent with high or low blood-sugar levels, placing people with T1D at risk for devastating complications such as heart attack, stroke, blindness, kidney disease and amputation. The Health Care and Social Assistance industry includes establishments and services such as:
hospitals, nursing and residential care facilities and out-patient care centres; offices of health practitioners (i.e. dentists, doctors, optometrists and chiropractors); medical and diagnostic laboratories; home health care services; ambulance services; social assistance services (i.e. for children, youth, the elderly, families); community food, housing, emergency and relief services; vocational rehabilitation services; and daycare services Indianapolis has the nickname “Naptown” because throughout its history many people have viewed the city as a rather slow and not-so-exciting place. It also received that nickname in part because Indianapolis can be long and difficult to say with six syllables, while Nap Town is considerably more pithy. It’s believed that Indianapolis being called Nap Town was popularized by jazz musicians in the 1930s. In the 1960s local radio personalities were encouraged to use the nickname frequently in order to downplay it and its negative connotations. More recently, the growth of Indianapolis, as well as the fact that the city hosted the Super Bowl in 2012, have allowed the city to escape its reputation as a sleepy city. JDRF is the leading global organization funding type 1 diabetes (T1D) research. JDRF’s goal is to progressively remove the impact of T1D from people’s lives until we achieve a world without T1D. JDRF has led the search for a cure for T1D since our founding in 1970. In those days, people commonly called the disease “juvenile diabetes” because it was frequently diagnosed in, and strongly associated with, young children. Our organization began as the Juvenile Diabetes Foundation. Later, to emphasize exactly how we planned to end the disease, we added a word and became the Juvenile Diabetes Research Foundation.Today, we know an equal number of children and adults are diagnosed every day—approximately 110 people per day.
It makes sense to mention the main issues –
advocating for government support,TRIAD study,Research Summit,Humulin R,gestational diabetes,Blood Glucose Level,SDP,diabetes death rate,2-h PG value,Medical Device,prone to ketoacidosis,nonprofit funder,Indiana,Insulin Nation,diabetes diagnosis,donate to help,Celiac Disease and Diabetes,stroke,Apidra,Medtronic Minimed Insulin Pump Users,impaired glucose tolerance,glucose tolerance,low blood glucose,diabetes distress,engage,diabetes educator,The Hyperglycemia and Adverse Pregnancy Outcome Study,sugar breakdown,Maturity-onset diabetes of the young,Insulin injections,GLP-1 agonists,SGLT2 inhibitors,insulin pumps,hyperosmolar hyperglycemic nonketotic syndrome,Government Advocacy,Robert Wood Johnson IV,diabetes mellitus,Sodium–glucose cotransporter 2 inhibitors,Insulin Therapy,ACCORD Study,ASPIRE Trial,Clinicians,Oral Glucose Tolerance Test,contribute,T1D burden,Weight Loss Support,Type 1 Diabetes Dictionary,Global Diabetes Research,US-IN,Aldesleukin,insulin deficiency,lente insulin,Type 2 Diabetes,brittle diabetes,antihyperglycemic agents,Indi-no-place,Treatment Advocacy,Insulin,donate,fundraising,Beta Cell Regeneration,symptoms of.